| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(98)00352-1 |
| P698 | PubMed publication ID | 10367952 |
| P2093 | author name string | Norrby SR | |
| Braconier JH | |||
| Wennerholm S | |||
| P2860 | cites work | Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease | Q42673894 |
| Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. | Q45760101 | ||
| The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults | Q47305437 | ||
| Hepatitis A infection: a seroepidemiological study in young adults in North-East Italy. | Q50906394 | ||
| An inactivated hepatitis A viral vaccine of cell culture origin | Q70138179 | ||
| Sensitive assays for hepatitis A antibodies | Q72663324 | ||
| Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine | Q73653658 | ||
| Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination | Q73671207 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2181-2184 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Comparative immunogenicity and tolerance of Vaqta and Havrix | |
| P478 | volume | 17 |
| Q74305688 | A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim |
| Q78569854 | A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses |
| Q30910692 | Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data |
| Q45343889 | Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose |
| Q24202104 | Hepatitis A immunisation in persons not previously exposed to hepatitis A |
| Q26765433 | Hepatitis Vaccines |
| Q47613191 | Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix®) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen®) for Japanese travelers to endemic countries |
| Q81488434 | Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine |
| Q50081935 | Interchangeability of Hepatitis A boosters, Avaxim and Vaqta, in healthy adults following a primary dose of the combined typhoid/Hepatitis A vaccine Viatim |
| Q51053523 | Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. |
| Q36238689 | Prevention of hepatitis A by Havrix: a review |
| Q73294580 | Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines |
| Q93092097 | Safety and immunogenicity of VAQTA® in children 12-to-23 months of age with and without administration of other US pediatric vaccines |
| Q45012673 | Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. |
Search more.